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Abstract
Background: Prion diseases are fatal neurodegenerative disorders that can arise sporadically, be genetically inherited or
acquired through infection. The key event in these diseases is misfolding of the cellular prion protein (PrP
C) into a
pathogenic isoform that is rich in b-sheet structure. This conformational change may result in the formation of PrP
Sc, the
prion isoform of PrP, which propagates itself by imprinting its aberrant conformation onto PrP
C molecules. A great deal of
effort has been devoted to developing protocols for purifying PrP
Sc for structural studies, and testing its biological
properties. Most procedures rely on protease digestion, allowing efficient purification of PrP27-30, the protease-resistant
core of PrP
Sc. However, protease treatment cannot be used to isolate abnormal forms of PrP lacking conventional protease
resistance, such as those found in several genetic and atypical sporadic cases.
Principal Findings: We developed a method for purifying pathological PrP molecules based on sequential centrifugation
and immunoprecipitation with a monoclonal antibody selective for aggregated PrP. With this procedure we purified full-
length PrP
Sc and mutant PrP aggregates at electrophoretic homogeneity. PrP
Sc purified from prion-infected mice was able
to seed misfolding of PrP
C in a protein misfolding cyclic amplification reaction, and mutant PrP aggregates from transgenic
mice were toxic to cultured neurons.
Significance: The immunopurification protocol described here isolates biologically active forms of aggregated PrP. These
preparations may be useful for investigating the structural and chemico-physical properties of infectious and neurotoxic PrP
aggregates.
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Introduction
Prion diseases are fatal degenerative disorders of the central
nervous system (CNS) that can arise sporadically, be genetically
inherited due to mutations in the gene encoding the prion protein
(PrP), or acquired through infection [1]. The majority of prion
diseases involve CNS accumulation of PrP
Sc, an abnormally folded
form of the cellular prion protein (PrP
C), which propagates itself by
seeding conformational conversion of PrP
C substrate molecules
[2,3].
PrP
Sc and PrP
C have distinct biophysical and biochemical
properties. PrP
Sc is rich in b-sheet structure, insoluble in mild
detergents, and partially resistant to digestion with proteinase-K
(PK), yielding a N-terminal truncated fragment of 27–30 kDa
(PrP27-30) [4–6]. In contrast, PrP
C has a predominant a-helix
structure [7], is soluble in detergents and PK-sensitive.
PrP
Sc is pathognomonic of prion infection; however, it may not
be the proximate cause of neurodegeneration [8]. Several genetic
prion diseases, in fact, develop in the absence of protease-resistant
PrP or in the presence of other abnormal forms of the protein, and
are not transmissible to laboratory animals [9–13]. Some sporadic
prion diseases have also been described that do not have PK-
resistant PrP in the CNS [14,15], reinforcing the idea that PrP
refolding into PrP
Sc is not required to induce neurodegeneration.
Experiments in transgenic (Tg) mice support the contention that
pathogenicity and infectivity are independent properties of
misfolded PrP, attributable to different conformational states of
the protein. Tg(PG14) mice carrying the mouse PrP homologue of
a 9-octapeptide repeat insertion linked to a genetic prion disease
develop a progressive neurological illness with massive apoptosis of
cerebellar granule neurons [16,17]. These mice synthesize a
misfolded form of mutant PrP in their brains that shows a high
tendency to aggregate but has considerably less protease resistance
than conventional PrP
Sc, and is not infectious [17–19]. When
inoculated with Rocky Mountain Laboratory (RML) prions,
however, Tg(PG14) mice accumulate a form of PG14 PrP that is
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mice, because it is highly PK-resistant, infectious in animal
bioassay and able to seed PrP
C misfolding in a protein misfolding
cyclic amplification (PMCA) reaction [18,19]. It is still not clear
what structural features distinguish infectious PG14 PrP from the
non-infectious form of the protein [19].
A number of methods have been developed for purifying PrP
Sc
from prion-infected animals for biological and structural analyses
[6,20–22]. Commonly used procedures are based on sequential
centrifugation of detergent brain extracts to concentrate insoluble
PrP
Sc molecules, and incubation with high concentrations of PK to
digest PrP
C and other proteins, yielding 60–90% pure PrP27-30
preparations. These protocols cannot be used to purify patholog-
ical PrP species lacking conventional PK resistance.
Here we describe a method for purifying aggregates of
misfolded PrP, based on immunoprecipitation with a monoclonal
antibody that recognizes structural epitopes common to both
infectious and non-infectious PrP [23–25]. This procedure can be
used to isolate aggregated full-length PrP
Sc molecules from prion-
infected mice, as well as neurotoxic PrP aggregates that
accumulate in the brains of Tg mice expressing pathogenic PrP
mutations. PrP preparations obtained with this method are highly
pure, and can be used for structural and physicochemical studies.
Results
Monoclonal Antibody 15B3 Reacts with Semi-Purified
PG14 PrP Aggregates
A common procedure for purifying PrP
Sc from prion-infected
brains consists of a series of sequential centrifugation gradually
enriching insoluble PrP [20,22] (Fig. 1A). This protocol is
commonly used to isolate PrP
Sc from infected Syrian hamsters,
which accumulate high levels of insoluble PrP in their brains
[6,26].
We used sequential centrifugation to purify insoluble mutant
PrP molecules from the brains of Tg(PG14) mice. To evaluate the
efficiency of purification, we assayed PrP in the different fractions
by Western blot, and compared the amount to the total amount of
proteins in the corresponding fraction, visualized by silver staining
(Fig. 1B and C). Insoluble PG14 PrP was highly enriched in the
final pellet (P3), which contained approximately 60% of total PrP
(Fig. 1B). However, PrP still accounted for a small proportion of
Figure 1. Aggregates of PG14 PrP can be enriched by sequential centrifugation. Brain homogenates from Tg(PG14) mice were fractionated
by the scheme shown in (A). (B) Proteins in the different fractions were Western blotted using anti-PrP antibody 3F4 (top panel), or separated by SDS-
PAGE and visualized by silver staining (bottom panel). (C) Proteins in the P3 fractions isolated from un-inoculated (2) or RML-infected (+) mouse
brains were separated by SDS-PAGE and visualized by silver staining. Brackets indicate the protein bands corresponding to PrP (lanes 1–3). Molecular
size markers are given in kilo-daltons. For this and all subsequent figures, results were reproduced in at least three independent experiments, each
using different mouse brains.
doi:10.1371/journal.pone.0007816.g001
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preparations were obtained when sequential centrifugation was
used to isolate PrP
Sc from the brains of RML-infected Tg(PG14)
or C57BL/6 mice (Fig. 1C, lanes 2 and 3). The P3 fraction from
the brains of PrP knockout mice (Prnp
0/0) showed a similar pattern
of bands (with the exception of the PrP-specific bands) (Fig. 1C,
lane 4), confirming that the P3 pellet contained a number of
detergent-insoluble proteins besides PrP.
Monoclonal antibody15B3 reacts selectively with PrP
Sc [23], as
well as with non-infectious aggregates of mutant PrP [24,25]. We
used this antibody to immunopurify PG14 PrP. To test whether
15B3 could selectively capture the protein from P3 fractions, we
used surface plasmon resonance (SPR). P3 fractions from Tg(PG14)
or Prnp
0/0 mice were injected onto SPR sensor chips in which
monoclonalantibody 15B3 or 3F4hadbeenimmobilized by amine-
coupling chemistry. A marked signal was observed when the PG14
PrP-containing fraction was flowed onto the 15B3-coated chip,
whereas no signal was observed with the Prnp
0/0 sample (Fig. 2A).
The 15B3-bound PG14 fraction showed a very slow dissociation
rate (4610
25 s
21, Fig. 2A), suggesting a high-affinity interaction.
No SPR signal was detected when the same P3 fractions were
flowed onto sensor chips coated with antibody 3F4 (Fig. 2B),
consistent with previous observations that the 3F4 epitope is
inaccessible in native PG14 PrP molecules [18,19]. These results
indicated that 15B3 selectively bound aggregated PG14 PrP with
high affinity, and could be used to immunopurify the protein.
Immunopurification of Pathological PrP Aggregates
Using Monoclonal Antibody 15B3
The P3 fraction from Tg(PG14) brains was immunoprecipitated
with antibody 15B3, and several procedures were tested to elute
PrP from the antibody without denaturing the protein. The
antigen-antibody binding is usually disrupted by basic (.9.0) or
acidic (,3.0) pH. Because these conditions may result in partial
protein denaturation, we used solutions with a pH between 8.5
and 4.0. Negligible amounts of PrP were eluted at pH 8.5 and 6.0
(Fig. 3A, lanes 2 and 4), but recovery reached a maximum of
,50% on lowering the pH to 5.0 or 4.0 (lanes 5 and 7).
We then tested procedures to improve PrP recovery. Subjecting
the magnetic beads to three sequential rounds of sonication in
phosphate-buffered saline (PBS) eluted more than 80% of
immunoprecipitated PG14 PrP (Fig. 3A, lane 9). The eluted
protein retained its aggregated state, as it partitioned in the pellet
fraction after ultracentrifugation at 180,0006 g, and was still
recognized by 15B3 in the SPR or immunoprecipitation assay
format (data not shown). SPR using known concentrations of
immunopurified PG14 PrP enabled us to estimate an equilibrium
dissociation constant (Kd) of 1–2 nM monomer equivalent.
However, since PG14 PrP is aggregated the actual affinity would
be higher, depending on the size of the aggregates (e.g.
Kd=0.120.2 nM for decamers).
To assess the purity of the 15B3-immunoprecipitated aggregates,
purified fractions from uninoculate or RML-inoculated Tg(PG14)
mice, Tg(CJD) mice expressing the mouse homologue of the
D178N/V129 PrP mutation linked to Creutzfeldt-Jakob disease
(CJD) [27], and RML-infected C57BL/6 mice were subjected
to SDS-PAGE and analyzed by silver staining or Western blot
using anti-PrP antibodies (Fig. 3B and C). The majority of the
immunopurified protein bands were in the expected Mr between
20 and 40 kDa (Fig. 3B, top panel), and reacted with antibody
8H4, whose epitope is located in the C-terminal region of PrP
between residues 145 and 220 [28] (lower panel). A faint band
withanapparentMrof,60 kDawasalsodetectedby8H4(Fig.3B,
lower panel, and Fig. 3C, lanes 3 and 4). This band could be clearly
seen in silver-stained gels after longer exposure (Fig. 3C, lanes 1
and 2), and probably corresponded to SDS-resistant PrP dimers
previously observed in prion-infected tissues [29]. Several PrP
bands of low Mr were observed only in purified PrP
Sc preparations
from RML-infected mice (Fig. 3B, lanes 3 and 4, and Fig. 3C).
These bands did not react with an antibody that recognizes
mouse PrP sequence 45–66 (not shown) [30], suggesting that
they corresponded to N-terminally truncated PrP generated
by proteolysis of PrP
Sc in infected brains [19,31]. No proteins
were detected in immunopurified samples from Prnp
0/0 mice
(Fig. 3B, lane 5), confirming that the 15B3 antibody did not bind
other insoluble proteins in the P3 fraction. To further assess the
purity of the immunopurified preparations, we used MALDI-TOF
mass spectrometry, and found that the only identifiable protein was
PrP (probability-based MOWSE Mascot score: 85; matched
peptides: 13; sequence coverage: 30%).
Comparative densitometric analysis of immunopurified PrP
with serial dilutions of recombinant PrP as a standard (not shown)
indicated a protein recovery rate of ,1 mg per mouse brain.
Figure 2. Surface plasmon resonance shows that monoclonal
antibody 15B3 selectively captures PG14 PrP aggregates from
P3 fractions. Fractions P3 prepared from whole brains of Tg(PG14) or
Prnp
0/0 mice were perfused for 5 min (bars) over the sensor surface of
SPR chips on which antibody 15B3 (A) or 3F4 (B) had been immobilized.
The sensorgrams (time course of the SPR signal in Resonance Units, RU)
refer to the specific binding to the antibody (binding was negligible on
sensor surfaces without antibody). Significant binding was detected
when P3 fractions containing PG14 PrP (black line) were flowed over the
15B3-coated chip (A), but not on the 3F4-coated chip (B). No binding was
observed when a P3 fraction from Prnp
0/0 mice was analyzed (gray line).
doi:10.1371/journal.pone.0007816.g002
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Sc Aggregates Seed Misfolding of PrP
C
To test whether immunopurified PrP
Sc aggregates were able to
seed misfolding of PrP
C we used PMCA technology [3,32,33]. A
brainhomogenate fromTg(WT)mice expressing3F4-tagged mouse
PrP
C [16] was seeded with PrP
Sc immunopurified from RML-
infected C57BL/6 mice (which does not contain the 3F4 epitope),
and the mixture was subjected to 90 cycles of sonication and
incubation at 37uC. After PK digestion to eliminate the residual
PrP
C substrate, the reactions were analyzed by Western blotting
using antibody 3F4 to detect only newly formed protease-resistant
PrP. Purified PrP
Sc aggregates, either in solution or immobilized on
glass coverslips, seeded the formation of PK-resistant PrP (Fig. 4,
lanes 4 and 8). Control PMCA reactions without sonication (Fig. 4,
lanes 2 and 6), or seeded with immunoprecipitates from Prnp
0/0
mice (lanes 9–12), did not produce any protease-resistant PrP.
These results indicated that immunopurified PrP
Sc was able to
propagate its conformation in vitro.
Mutant PrP Aggregates Are Toxic to Cultured Neurons
Thereisevidencethat purified preparationsofPrP27-30aretoxic
to cultured neurons [34–36]. We tested the effect of immunopur-
ified PrP aggregates on the viability of cortical neurons cultured
from newborn C57BL/6 mice. Cells were exposed to PrP
aggregates (,15 nM) isolated from the brains of Tg(PG14) or
Tg(CJD) mice, and neuronal viability was assayed after seven days.
There was a statistically significant toxic effect (Fig. 5). Neuronal
viability approximately halved in aggregate-treated cells, whereas
no toxicity was observed when cells were exposed to the vehicle
alone (PBS), or to 15B3-immunoprecipitated fractions from Prnp
0/0
mice.
Discussion
We have developed a protocol for purifying pathological PrP
aggregates based on immunoprecipitation with a monoclonal
antibody that recognizes structural features common to infectious
and non-infectious forms of misfolded PrP. This method yields
electrophoretically homogeneous PrP preparations without the
need for protease digestion, and can be used to purify full-length
PrP
Sc molecules, as well as other misfolded forms of the protein
that lack infectivity and protease-resistance. The purified mole-
cules retain their native biological properties, including the ability
to seed misfolding of PrP
C by PMCA and neurotoxicity, and are
suitable for structural and physicochemical studies.
Standard protocols for isolating PrP
Sc involve sequential
centrifugation of detergent brain extracts to concentrate insoluble
molecules, and PK digestion to eliminate PrP
C and other
contaminating proteins, and enrich protease-resistant PrP. These
methods are commonly used to purify PrP
Sc from prion-infected
Syrian hamsters (typically inoculated with the 263K strain), which
accumulate high levels of insoluble and protease-resistant PrP in
their brains. The purity of PrP
Sc obtained with these procedures
varies between 60 and 90%, depending on the characteristics of
the prion strain, stage of disease of the animal, and the conditions
in which the brains have been collected and stored [22]. Although
PK readily digests most detergent-extracted proteins, ferritin can
withstand even harsh PK treatment and often contaminates the
final PrP
Sc preparation [37]. Moreover, due to protease treatment,
the purified PrP
Sc protein lacks 65–70 aminoacids of the N-
terminus. Hamster PrP
Sc has also been purified by immunoaffinity
chromatography [21]; however, this method used antibodies that
recognize both PrP
C and PrP
Sc, and required PK digestion to
isolate protease-resistant PrP
Sc.
The protocol described here offers at least two major
advantages over previous procedures. First, it consistently yields
highly pure PrP preparations, independently of the amount of
insoluble and protease-resistant PrP in the starting material.
Second, since it does not require protease digestion, it can be used
to purify different kinds of pathological PrP, including full-length
PrP
Sc molecules, as well as other abnormally folded forms that lack
protease resistance.
The immunopurification method is straightforward and repro-
ducible. Similarly to other procedures it requires a series of
centrifugations to enrich insoluble PrP, then a single immunopre-
cipitation step with monoclonal antibody 15B3 (Fig. 6A). This
Figure 3. 15B3 immunoprecipitation yields pure preparations
of infectious and non-infectious mouse PrP aggregates. (A) PrP
aggregates were immunoprecipitated from P3 fractions of Tg(PG14)
brains with antibody 15B3. PG14 PrP eluted (E lanes) by incubation in
0.1 M Tris-Glycine buffer at different pH (lanes 1–7) or by sonication in
PBS (lanes 8–9), and the residual protein eluted by boiling the
Dynabeads in SDS (B lanes), were detected by Western blotting with
anti-PrP antibody 3F4. (B) PrP aggregates, immunopurified and eluted
by sonication, from un-inoculated Tg(PG14) (lane 1) and Tg(CJD) (lane
2) mice, or RML-infected C57BL/6 (lane 3) and Tg(PG14) (lane 4) mice
were visualized by silver staining (top panel) or by Western blotting
(bottom panel) using anti-PrP antibody 8H4. No protein bands were
detected when the purification was done using Prnp
0/0 mouse brains
(lane 5). (C) Two samples of PrP
Sc immunopurified from RML-infected
C57BL/6 mice were run on SDS-PAGE, and the gels stained to saturation
with silver (lanes 1–2) or immunoblotted with antibody 8H4 (lanes 3–4).
doi:10.1371/journal.pone.0007816.g003
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PrP from a wide range of species, including hamster, mouse,
bovine and human [23–25]. Immunoprecipitated PrP is efficiently
eluted by sonication, which probably breaks up the aggregates into
smaller units, without disrupting the antigen-antibody binding
(Fig. 6B). The eluted aggregates retain reactivity to antibody 15B3,
and the ability to seed misfolding of PrP
C by PMCA, indicating
that the structural feature that determine the 15B3 epitope and the
converting activity of the purified protein are preserved. In
addition, the immunopurified aggregates are toxic to cultured
neurons, similar to PrP
Sc from infected hamsters [34–36], and b-
folded oligomers of synthetic or recombinant PrP [38–43].
We show that 15B3 immunoprecipitation can be used to purify
aggregated forms of mutant PrP that accumulate in the brains of
spontaneously ill or RML-infected Tg(PG14) mice. In previous
studies we analyzed PrP in brain homogenates of these mice using
a panel of biochemical assays to try and identify structural
differences between non-infectious and infectious forms of the
protein. Surprisingly, we found that despite their marked
difference in protease resistance both forms of PG14 PrP behave
identically in a variety of biochemical tests for protein conforma-
tion and oligomeric state [19]. These results suggest that more
subtle molecular differences distinguish infectious from non-
infectious PrP. The nature of these differences can now be
investigated using the immunopurified material described here
which, for example, can be analyzed by atomic force microscopy,
Fourier-transformed infrared spectroscopy, and mass spectrometry
(our preliminary observations).
In conclusion, we have developed a procedure for obtaining
pure preparations of aggregated PrP from different mouse models
Figure 4. Immunopurified aggregates of PrP
Sc support in vitro misfolding of PrP
C by PMCA. Aggregates of PrP
Sc immunopurified from P3
fractions of RML-infected C57BL/6 mice (lanes 1–8), or immunoprecipitates of P3 fractions of Prnp
0/0 mice (lanes 9–12) were resuspended in PBS
(lanes 1–4 and 9–12) or immobilized on glass coverslips by ultracentrifugation (lanes 5–8), and mixed with brain homogenates of Tg(WT) mice
overexpressing 3F4-tagged PrP
C. Mixtures were either rapidly frozen (lanes 1 and 2, 5 and 6, 9 and 10) or subjected to 90 cycles of sonication/
incubation (lanes 3 and 4, 7 and 8, 11 and 12). Samples were then either subjected to proteinase K (PK) (lanes 2, 4, 6, 8, 10 and 12), or left undigested
(lanes 1, 3, 5, 7, 9 and 11). All samples were analyzed by Western blotting with 3F4 antibody.
doi:10.1371/journal.pone.0007816.g004
Figure 5. Mutant PrP aggregates from Tg(PG14) and Tg(CJD)
mice are toxic to primary neurons. Cortical neurons from C57BL/6
mice were exposed to ,15 nM of PrP aggregates purified from
Tg(PG14) and Tg(CJD) mice, to the vehicle alone (PBS), or to 15B3-
immunoprecipitated P3 fractions from Prnp
0/0 mice. Cell survival was
quantified by MTT assay after seven days, and expressed as a
percentage of untreated cells. Data are the mean6SEM of 8–24
replicates from three independent experiments. **p,0.005 and
***p,0.0001 vs. untreated (Mann-Whitney test).
doi:10.1371/journal.pone.0007816.g005
Figure 6. Diagram of the 15B3-immunopurification procedure.
The scheme summarizes the main steps of the purification protocol (A),
and illustrates the putative mechanism by which sonication elutes
aggregated PrP from 15B3-coated beads (B).
doi:10.1371/journal.pone.0007816.g006
Prion Aggregates Purification
PLoS ONE | www.plosone.org 5 November 2009 | Volume 4 | Issue 11 | e7816of prion disease, even those that accumulate abnormal forms of
PrP that lack infectivity and/or protease resistance. Comparative
analysis of purified PrP aggregates with different biochemical and
biological properties could provide important information on their
molecular nature and role in pathology.
Materials and Methods
Mice
All procedures involving animals and their care were conducted
according to European Union (EEC Council Directive 86/609,
OJ L 358,1; 12 December 1987) and Italian (D.L. n.116, G.U.
suppl. 40, 18 February 1992) laws and policies, and in accordance
with the United States Department of Agriculture Animal Welfare
Act and the National Institute of Health (Bethesda, MA, USA)
policy on Humane Care and Use of Laboratory Animals, and they
were approved by the Animal Care Committee of the Department
of Neuroscience at Mario Negri Institute (Milan, Italy).
Production of Tg mice expressing WT, PG14, or D177N/V128
mouse PrP tagged with an epitope for the monoclonal antibody
3F4 has been reported elsewhere [16,27]. These Tg mice were
originally generated on a C57BL/6J X CBA/J hybrid back-
ground, and were subsequently bred with the Zurich I line of
Prnp
0/0 mice [44]. The resulting animals therefore express
transgenically encoded but not endogenous mouse PrP.
For studies involving prion-infected mice, the RML isolate of
scrapie (obtained from Byron Caughey and Richard Race, Rocky
Mountain Laboratories, Hamilton, MT, USA) was passaged
repeatedly in CD1 (Swiss) mice. Ten-percent (w/v) homogenates
of mouse brain were prepared using a glass/Teflon apparatus (10
strokes at 1000 rpm) in ice-cold PBS. After being cleared by
centrifugation at 9006g for 5 min, the homogenates were diluted
to 1% in PBS, and 25 ml was injected intracerebrally into the right
parietal lobe of weanling mice using a 25-gauge needle.
Primary Neuronal Cultures
Cortical neurons were prepared from two-day-old C57BL/6
mice as described [45]. Briefly, brain tissue was sliced into ,1m m
pieces and incubated in 5.8 mM MgCl2, 0.5 mM CaCl2, 3.2 mM
HEPES, 0.2 mM NaOH (pH 7.4, 292 mOsm), containing 1 mg/
ml papain (Sigma) at 34uC for 30 min. Dissociated cells were
plated at 70,000 cells/well on poly-D-lysine-coated (0.05 mg/ml)
96-well plates, and maintained in Neurobasal Basal Medium
(Gibco) supplemented with B27 (Gibco), penicillin/streptomycin
and glutamine 2 mM (Gibco), at 37uC in an atmosphere of 5%
CO2, 95% air. Cell viability was assessed by measuring the level of
3-(4,5 dimethylthiazol-2-yl)-2,5-diphemyl tetrazolium bromide
(MTT) to formazan, as described [40].
Sequential Centrifugation
Mouse brain homogenates were fractionated as described [19].
Brains were cut into small pieces, washed with PBS, homogenized
with 3 ml of 10% sarcosine in TEND (10 mM Tris-HCl pH 8,
1 mM EDTA, 130 mM NaCl, and 1 mM dithiothreitol) contain-
ing a protease inhibitors cocktail (Cat. N. 1-836-153; Roche,
Indianapolis, IN, USA), then incubated on ice for 1 h and
centrifuged at 22,0006g for 30 min at 4uC. The supernatant was
incubated on ice, while the pellet was resuspended in 1 ml of 10%
sarcosine in TEND, incubated for 1 h on ice, and centrifuged at
22,0006g for 30 min at 4uC. The pellet (P0) was collected while
the two supernatants were combined and centrifuged at
150,0006 g for 2.5 h at 4uC. The new supernatant (S0) was
removed and collected for further analysis, while the pellet was
rinsed with 50 ml of 100 mM NaCl, 1% sulfobetaine (SB) 3-14,
TEND plus protease inhibitors, resuspended in 1 ml of the same
buffer, and centrifuged at 180.0006 g for 2 h at 20uC. The
supernatant (S1) was removed and collected, and the pellet was
rinsed with 50 ml of TMS (10 mM Tris-HCl pH 7.0, 5 mM
MgCl2, and 100 mM NaCl) plus protease inhibitors, resuspended
in 600 ml of the same buffer containing 100 mg/ml RNAse A and
incubated for 2 h at 37uC. The sample was then incubated with
5 mM CaCl2,2 0mg/ml DNAse I for 2 h at 37uC. To stop the
enzymatic digestion, EDTA was added to a final concentration of
20 mM, and the sample was mixed with an equal volume of TMS,
1% SB 3-14.
The sample was deposited gently on a 100-ml cushion of 1 M
sucrose, 100 mM NaCl, 0.5% SB 3-14, and 10 mM Tris-HCl
pH 7.4, and centrifuged at 180,0006 g for 2 h at 4uC. The
supernatant (S2) was collected and the pellet was rinsed with 50 ml
of 0.5% SB 3-14, PBS, resuspended in 100 ml of the same buffer,
subjected to 365 s pulses of bath sonication with a Bandelin
Sonopuls Ultrasonicator (Amtrex Technologies, Saint-Laurent,
QC, Canada) at 90% power, and centrifuged at 180.0006 g for
15 min at 4uC. The final supernatant (S3) was collected and the
pellet (P3) was resuspended in 100 ml of 0.5% SB 3-14, PBS.
Immunoprecipitation with 15B3
A 500-ml aliquot of mouse anti-IgM Dynabeads (Dynal,
Carlsbad, CA, USA) and 250 mg of mAb 15B3 (Prionics, Zurich,
CH) [23] were diluted with 1 ml of PBS containing 0.1% of bovine
serum albumin (BSA), incubated for 2 h, washed three times with
1 ml of PBS and resuspended in 500 ml of PBS; 100 ml of 15B3-
coated Dynabeads were then added to the resuspended P3
fractions. Each sample was incubated on a rotating wheel for 24 h
at 4uC, after which beads were washed once with 1 ml of Wash
Buffer (Prionics) and twice more with PBS. Beads were
resuspended in 500 ml of PBS and then subjected to 3630 s
pulses of sonication using a bath microsonicator at 50% of power
(Model 3000; Misonix, Farmingdale, NY, USA) to elute
immunoprecipitated PrP. In order to increase the concentration
of the purified aggregates the sample was ultracentrifuged at
100,0006g for 15 min at 4uC, then resuspended in 100 ml of 0.5%
SB 3-14, PBS.
Western Blotting
PrP was detected in purified fractions by Western blotting. Each
sample was diluted 1:1 in 2X Laemmli sample buffer, heated at
95uC for 5 min, then resolved by sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE). Proteins were
electrophoretically transferred to poly-vinylidene fluoride (PVDF)
membranes, and the membranes were blocked for 10 min in 5%
(w/v) non-fat dry milk in Tris-buffered saline containing Tween
20. After incubation with appropriate primary and secondary
antibodies, signals were revealed using enhanced chemilumines-
cence (Amersham Biosciences), and were visualized by a Biorad
XRS image scanner. Anti-PrP antibodies 3F4 [46] or 8H4 [28]
were used to develop Western blots, as indicated in the figure
legends.
Silver Staining of Purified Fractions
Two ml of purified aggregates was diluted in 10 ml of Laemmli
sample buffer and 4% urea, heated at 95uC for 10 min, then
resolved by SDS-PAGE using 12% polyacrylamide gels. Gels were
stained with Silver Snap (Pierce, Rockford, IL, USA) following the
manufacturer’s instructions. Murine recombinant PrP 23–231,
used for indirect quantification of purified PrP aggregates, was
expressed and purified according to the procedure of Zahn et al.
[47] and stored in 50 mM sodium acetate, pH 4.0.
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Principles and details of the automated version of PMCA have
been described elsewhere [33]. In our experimental conditions,
Tg(WT-E1) brains were used as the source of 3F4-tagged PrP
C
substrate. Ten-percent (w/v) brain homogenates were prepared in
conversion buffer (PBS containing NaCl 150 mM, 1.0% Triton X-
100, 4 mM EDTA, plus EDTA-free protease inhibitors). The
samples were clarified by centrifugation at 3006 g for 30 s in a
tabletop centrifuge. One ml of PrP
Sc aggregates purified from
RML-inoculated C57BL/6 mice (which produce non-3F4 tagged
PrP
Sc) was directly mixed (1:200) with Tg(WT-E1) brain
homogenate and loaded into 0.2-ml PCR tubes.
In an alternative setting,1 mlo fP r P
Sc aggregates was immobilized
on a glass coverslip by ultracentrifugation at 150,0006g for 1 h at
4uC, then used for seeding the PMCA reaction. Tubes were
positioned on an adaptor placed on the plate holder of a
microsonicator (Model 3000; Misonix). The sonicator was pro-
grammed to perform 90 cycles of 30 min incubation at 37uC
followed by a 40 s pulse of sonication at 60% power. Tubes were
incubated without shaking, immersed in the sonicator bath, and the
entire microplate horn was kept inside an incubator at 37uC. After
completion of the PMCA reaction, 10 ml of each sample was diluted
in PK digestion buffer (Tris-HCl 50 mM pH 8.5, 150 mM NaCl)
and incubated with 50 mg/ml of PK at 37uC for 1 h on an end-over-
end rotator before Western blotting with anti-PrP antibody 3F4.
Surface Plasmon Resonance
SPR studies were carried out using the ProteOn XPR36 Protein
Interaction Array system (Bio-Rad) [48]. Antibodies 15B3 and 3F4
were covalently immobilized in two parallel strips of the same GLC
sensor chip (Bio-Rad), using amine-coupling chemistry. The chip
surfaces were activated for 5 min with a mixture of 1-[3-
(dimethylamino)propyl]- 3-ethylcarbodiimide hydrochloride (EDC,
0.2 M) and sulfo-N-hydroxysuccinimide (sulfo-NHS 0.05 M) (Bio-
Rad); this was followed by injection of 3F4 (30 mg/ml in sodium
acetate, pH 5.0), or 15B3 (30 mg/ml in sodium acetate, pH 5.0),
which flowed for 5 min at a rate of 30 ml/min. The remaining
activated groups were blocked with a 5-min injection of 1 M
ethanolamine. The amounts of 3F4 or 15B3 covalently immobilized
onto the surface, expressed in Resonance Units (1 RU=1 pg
protein/mm
2), were about 6000 and 9000 RU, respectively. A
reference channel was prepared in parallel using the same
activation/deactivation procedure but injecting the vehicle only.
After the immobilization procedure, the fluidic system of
ProteOn is rotated by 90u to test in parallel up to six different
analytes over the target surfaces. P3 fractions isolated from the
brain of Tg(PG14) or Prnp
0/0 mice, or 200–400 ng of immuno-
purified PG14 PrP, were diluted in PBS containing 0.5% NP-40
and 0.5% sodium deoxycholate, sonicated for 30 s and injected at
a rate of 30 ml/min for 5 min. Vehicle was always injected in
parallel flow channels. All the analyses were done at 25uC. The
sensorgrams (time course of the SPR signal in RU) were
normalized to a baseline value of 0. The signals observed in the
surfaces immobilizing 15B3 or 3F4 were corrected by subtracting
the non-specific response observed in the empty reference surface.
Parallel injections of vehicle alone served to correct for binding-
independent responses (i.e. drift effects).
MALDI-TOF Mass Spectrometry and Protein Identification
Peptide mass fingerprinting (PMF) was performed on a Bruker
ReflexIII
TM MALDI-TOF mass spectrometer equipped with a
SCOUT 384 multiprobe inlet and a 337-nm nitrogen laser using
as matrix a-cyano-4-hydroxycinnamic acid (Bruker, Daltonics), as
described [49]. Data were subjected to NCBInr databases
searching using as programs Mascot (http://www.matrixscience.
com) allowing up to 1 missed trypsin cleavage and a mass
tolerance of 60.1 Da. In Mascot program, probability-based
MOWSE scores [50] greater than 61 were considered significant
(p,0.05) searching Mus musculus sequences deposited in NCBInr.
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